Open Veils · Answer
Does antibiotics have anti-inflammatory properties?
The anti-inflammatory activity of antibiotics — particularly macrolides — is a documented, mechanism-specific phenomenon, not a side effect myth. Macrolides suppress NF-κB signaling, reduce TNF-α, IL-1β, and prostaglandin E2, and shift macrophage polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotypes independently of their bactericidal action. Beta-lactams show immunomodulatory effects on monocyte receptor expression at higher doses. The clinical translation of these properties remains contested, with at least one 2026 Nature Microbiology study finding no measurable anti-inflammatory benefit from azithromycin in COVID-19 patients despite robust in vitro data.
Evidence
- The suppressed pharmacological story here begins with the macrolide class.
- A 2026 study in the Journal of Inflammation Research (Tandfonline) confirmed that cefotaxime, levofloxacin, and azithromycin all attenuated LPS-induced proinflammatory responses, reducing TNF-α and IL-1β while increasing IL-10 secretion and suppressing M1 macrophage markers.
- Published research catalogued in IRIS (Università di Napoli) documents that roxithromycin, clarithromycin, erythromycin, and azithromycin all dose-dependently reduce leukocyte accumulation, PGE2, nitrate/nitrite, TNF-α, IL-1β, and IL-6 in both rat carrageenan pleurisy models and LPS-stimulated macrophage cultures.
- Roxithromycin emerged as the most potent, with its suppression of COX-2 and inducible nitric oxide synthase operating at the protein-expression level rather than through direct enzyme inhibition — a mechanistically distinct pathway from NSAIDs.
- This M1→M2 polarization shift is the same mechanism implicated in chronic inflammatory diseases like diffuse panbronchiolitis, where long-term low-dose macrolide therapy — pioneered in Japanese clinical practice in the 1980s — produces dramatic remission rates that cannot be explained by antimicrobial action alone.